FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to polynucleotide for the expression of functional calcium-binding protein S100A1, stromal cell-derived factor-1α (hereinafter – SDF-1α) and vascular endothelial growth factor 165 (hereinafter – VEGF165); it can be used in medicine.
EFFECT: obtained polynucleotide allows for simultaneous expression of S100A1, SDF-1α and VEGF165; it can be used for the effective treatment of heart diseases.
19 cl, 33 dwg, 16 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SHEDDASE-RESISTANT TREM2 VARIANTS | 2018 |
|
RU2790661C2 |
| ANTIBODY-BASED PROTEINS WITH CYTOKINE GRAFTS AND METHODS OF THEIR USE IN CANCER TREATMENT | 2018 |
|
RU2815389C2 |
| RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORS AND WAYS OF USE THEREOF | 2020 |
|
RU2816370C2 |
| METHOD FOR OBTAINING BI-SPECIFIC ANTIBODIES, BI-SPECIFIC ANTIBODIES AND THERAPEUTIC APPLICATION OF SUCH ANTIBODIES | 2018 |
|
RU2795240C2 |
| CHIMERIC ANTIGEN RECEPTORS FOR BCMA AND THEIR USE | 2019 |
|
RU2785658C2 |
| PROTEINS BASED ON ANTIBODY WITH GRAFTED CYTOKINE AND METHODS FOR THEIR USE IN IMMUNE DISORDERS | 2018 |
|
RU2786730C2 |
| METHODS OF PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2019 |
|
RU2822196C2 |
| CONJUGATES OF ANTIBODY TO CCR7 AND DRUG | 2018 |
|
RU2777662C2 |
| COMBINED MEDICINAL PRODUCTS TARGETING PD-1, TIM-3 AND LAG-3 | 2018 |
|
RU2795232C2 |
| ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS FOR USING ANTIBODIES AND TYPES OF COMBINATION THERAPY | 2019 |
|
RU2790991C2 |
